Results 151 to 160 of about 175,700 (308)
Abstract Purpose To examine the direct and indirect costs associated with declining distance visual acuity (VA). Methods A longitudinal approach was applied to a large, nationally representative sample with extensive data, including VA measured at two time points.
Joonas Taipale +5 more
wiley +1 more source
Comprehensive Analysis of the Candidate GenesCCL2,CCR2, andTLR4in Age-Related Macular Degeneration [PDF]
Dominiek D. G. Despriet +11 more
openalex +1 more source
Mesopic microperimetry in Stargardt disease: Application and reliability
Abstract Purpose Mesopic microperimetry (mMP) is a promising functional endpoint in clinical trials for Stargardt disease type 1 (STGD1). This study evaluated the test–retest variability of mMP and influencing factors, which is essential for ensuring reliability in future STGD1 trials.
Sybren H. Kootstra +12 more
wiley +1 more source
Drusen morphometrics on optical coherence tomography in eyes with age-related macular degeneration and normal aging [PDF]
Deniz Oncel +8 more
openalex +1 more source
Abstract Purpose To investigate changes in choroidal and retinal thickness before and during myopia control treatment with orthokeratology lenses (OKL) in myopic children. Methods This was a sub‐study of CONTROL and CONTROL2 studies. The present study was a 2‐year, prospective, single‐group interventional study consisting of a 6‐month pre‐treatment ...
P. O. Hansen, F. Møller, T. M. Jakobsen
wiley +1 more source
Deep Learning‐Based Detection of Reticular Pseudodrusen in Age‐Related Macular Degeneration
ABSTRACT Background Reticular pseudodrusen (RPD) signify a critical phenotype driving vision loss in age‐related macular degeneration (AMD). This study sought to develop and externally test a deep learning (DL) model to detect RPD on optical coherence tomography (OCT) scans with expert‐level performance.
Himeesh Kumar +26 more
wiley +1 more source
ABSTRACT Background To evaluate the 10‐year cumulative incidence, progression rates, and risk factors for macular atrophy (MA) in neovascular age‐related macular degeneration (nAMD) patients receiving long‐term anti‐vascular endothelial growth factor (VEGF) therapy.
Francesco Romano +13 more
wiley +1 more source

